Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation. 1997

B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
ECMO Center Graz (Department of Neonatology), University of Graz, Austria. berndt.urlesberger@kfunigraz.ac.at

The purpose of this experimental study was to compare heparin-coated versus non-coated systems for extracorporeal membrane oxygenation (ECMO), to investigate the dynamic course of clotting activation in both groups. METHODS Eight pigs weighing 19.7 (+/- 1.3) kg, each underwent ECMO for 24 hours. Two groups were formed: in group 1, heparin-coated circuits were used with low dose heparinization (10 IU/kg/hr), whereas in group 2 non-coated circuits with high dose heparinization (60 IU/kg/hr) were used. Coagulation was monitored by measuring prothrombin time, partial thromboplastin time, fibrinogen, antithrombin III (AT III) and specific markers of clotting activation (thrombin-antithrombin III complexes (TAT) and D-dimer). Furthermore, platelet count, hematocrit, activated clotting time (ACT), and plasma heparin concentration were determined regularly RESULTS The dynamic course of the specific coagulation activation markers showed some differences: whereas TAT and D-dimer increased quickly in group 2, the increase in group 1 was delayed. Activation marker values tended to be lower in group 1 during the first six hours, after which no more differences between the groups were seen. After 24 hours of ECMO, TAT and D-dimer had nearly returned to baseline values. Platelets showed a continuous decrease throughout the experiment, which was very similar in both groups. CONCLUSIONS The heparin coated system showed a distinct delay in clotting activation during the first six hours of ECMO. After six hours there were no more differences between the groups.

UI MeSH Term Description Entries
D008297 Male Males
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell

Related Publications

B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
November 1991, The International journal of artificial organs,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
November 2009, Recent patents on cardiovascular drug discovery,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
January 1992, The International journal of artificial organs,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
January 1990, Intensive care medicine,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
February 1993, The Thoracic and cardiovascular surgeon,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
April 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
December 1997, The Thoracic and cardiovascular surgeon,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
December 2000, Osaka city medical journal,
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
January 1998, ASAIO journal (American Society for Artificial Internal Organs : 1992),
B Urlesberger, and G Zobel, and S Rödl, and D Dacar, and I Friehs, and B Leschnik, and W Muntean
September 1993, The Journal of thoracic and cardiovascular surgery,
Copied contents to your clipboard!